March 1, 2018 Journal article Open Access

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Valpione, Sara; Carlino, Matteo S.; Mangana, Johanna; Mooradian, Meghan J.; McArthur, Grant; Schadendorf, Dirk; Hauschild, Axel; Menzies, Alexander M.; Arance, Ana; Ascierto, Paolo A.; Di Giacomo, AnnaMaria; de Rosa, Francesco; Larkin, James; Park, John J.; Goldinger, Simone M.; Sullivan, Ryan J.; Xu, Wen; Livingstone, Elisabeth; Weichenthal, Michael; Rai, Rajat; Gaba, Lydia; Long, Georgina V.; Lorigan, Paul

Abstract Background Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy. Patients and methods One hundred sixteen metastatic melanoma patients who received BRAFi-based therapy and, after a break, were rechallenged with BRAFi ± MEKi at 14 centres in Europe, US and Australia were studied, respectively. Response rate (RR), overall survival (OS) and progression-free survival (PFS) from the start of retreatment were calculated. Results The median duration of treatment was 9.4 months for first BRAFi ± MEKi treatment and 7.7 months for the subsequent treatment (immunotherapy 72%, other 17%, drug holiday 11%) after BRAFi discontinuation. Brain metastases were present in 51 (44%) patients at BRAFi retreatment. The RR to rechallenge with BRAFi ± MEKi was 43%: complete response (CR) 3%, partial response (PR) 39%, stable disease (SD) 24% and progressive disease 30%, 4% missing. Of 83 patients who previously discontinued BRAFi due to disease progression, 31 (37.3%) responded (30 PR and 1 CR) to retreatment. The median OS from retreatment was 9.8 months, and PFS was 5 months. Independent prognostic factors for survival at rechallenge included number of metastatic sites (hazard ratio [HR] = 1.32 for each additional organ with metastases, P  Conclusion Rechallenge with BRAFi ± MEKi results in a clinically meaningful benefit and should be considered for selected patients.